Shots:

• The approval is based on the two P-II studies i.e., HQP1351CC201 & HQP1351CC202 study to evaluate olverembatinib in patients with T315I-mutant CML-CP or CML-AP prior treatment with BCR-ABL1 TKIs
• The results showed that patients treated with olverembatinib were efficacious & well-tolerated while the probability & depth of clinical response will increase with a prolonged treatment period
• Olverembatinib is a third-generation BCR-ABL inhibitor that is developed by Ascentage with support from the National Major New Drug Discovery & Manufacturing program which will co-commercialize in China by both companies. The therapy has received ODD from the US FDA & EMA while FTD from the US FDA

Ref: PR Newswire | Image: Ascentage